Xellia Pharmaceuticals ApS

Our purpose is to save lives

Xellia is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals.

Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production as well as research and development that promote long-term sustainability. Xellia is committed to conducting business responsibly and we continuously strive to reduce our impact on the environment in our value chain and to develop and maintain ethical supplier relationships.

Billede

Our people make us what we are

We strongly believe that the success of our business is attributed to our employees’ skills and experiences.

As a truly international company, we benefit from a diverse and multicultural workforce. At Xellia, we believe in the freedom to be yourself, and to bring the whole of your identity to the workplace.

We aim to attract the most passionate employees in our industry, and we support and encourage our employees through comprehensive people processes ensuring that every employee is treated fairly and has a voice which is listened to and valued.

Be part of a strong heritage

Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience.

With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.